Accumulated Losses and Seven Consecutive Years of Net Losses
First written in FY2017. 19 of 25 entries say "Worsened", first in FY2018-Q2. Latest entry: 2026-08-13.
Medinet moved to the "Worse" side of this theme in 2017, 3 years before the typical company in this theme (2020).
The whole theme swung hardest in 2021: 8 of 10 companies on the "Worse" side.
1 other company's latest entry also says "Mitigated".
- 2026-08-13MitigatedEarnings
「Quarterly net loss was ¥845 million, compared with a quarterly net loss of ¥1,111 million in the same period of the previous year.」
Quarterly net loss continued, but narrowed from the same period of the previous year. - FY2025WorsenedAnnual report
「The net loss was ¥1,362 million, compared with a net loss of ¥1,276 million in the previous fiscal year.」
The net loss expanded from ¥1,276 million in the previous fiscal year to ¥1,362 million, and losses continued to be recorded. - FY2024-Q2The quarterly net loss narrowedAnnual report
「The quarterly net loss was ¥634 million, compared with a quarterly net loss of ¥676 million in the same period of the previous year.」
The quarterly net loss narrowed from ¥676 million in the same period of the previous year to ¥634 million, but losses continued to be recorded. - FY2024-Q1The quarterly net loss narrowedAnnual report
「The quarterly net loss was ¥292 million, compared with a quarterly net loss of ¥325 million in the same period of the previous year.」
The quarterly net loss narrowed from ¥325 million in the same period of the previous year to ¥292 million, but losses continued to be recorded. - FY2023WorsenedAnnual report
「The net loss was ¥1,437 million, compared with a net loss of ¥1,254 million in the previous fiscal year.」
The net loss expanded from ¥1,254 million in the previous fiscal year to ¥1,437 million, and losses continued to be recorded even after the accumulated deficit was offset. - FY2023-Q3WorsenedAnnual report
「The quarterly net loss was ¥1,045 million, compared with a quarterly net loss of ¥988 million in the same period of the previous year.」
The Company also posted a quarterly net loss of ¥1,045 million for the cumulative third-quarter period, and the ongoing losses increased from the same period of the previous year. - FY2023-Q2RestatedAnnual report
「The quarterly net loss was ¥676 million, compared with a quarterly net loss of ¥678 million in the same period of the previous year.」
The Company also posted a quarterly net loss of ¥676 million for the cumulative second-quarter period, and losses continued to be recorded. - FY2023-Q1WorsenedAnnual report
「Total net assets decreased by ¥469 million from the end of the previous fiscal year, due to a ¥325 million decrease in retained earnings accompanying the recording of a quarterly net loss and a ¥143 million decrease in the valuation difference on other securities.」
The Company also posted a net loss of ¥325 million in the first quarter, and the accumulated deficit in retained earnings at the end of the quarter expanded from ¥2,093 million to ¥2,419 million. The accumulated deficit was separately offset on 31 January 2023. - FY2022WorsenedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The net loss was ¥1,254 million, and the deficit in retained earnings carried forward was ¥2,093.633 million, resulting in an expansion of losses and the accumulated deficit. - FY2022-Q3WorsenedAnnual report
「Retained earnings decreased from negative ¥843.396 million at the end of the previous fiscal year to negative ¥1,828.284 million due to a quarterly net loss of ¥988.743 million.」
Due to a quarterly net loss of ¥988.743 million, the accumulated deficit in retained earnings expanded from ¥843 million to ¥1,828 million. - FY2022-Q2WorsenedAnnual report
「Retained earnings decreased from negative ¥843.396 million at the end of the previous fiscal year to negative ¥1,518.470 million due to a quarterly net loss of ¥678.928 million.」
The Company also posted a net loss of ¥678.928 million for the cumulative second-quarter period, and the accumulated deficit in retained earnings expanded from ¥843 million to ¥1,518 million. - FY2022-Q1WorsenedAnnual report
「The quarterly net loss was ¥342.144 million.」
The Company also posted a net loss of ¥342 million in the first quarter, and the accumulated deficit in retained earnings expanded from ¥843 million to ¥1,181 million. - FY2021-Q3RestatedAnnual report
「The quarterly net loss was ¥548.783 million.」
Even after the accumulated deficit was offset, the Company posted a net loss of ¥548 million for the cumulative third-quarter period, and losses continued to be recorded. - FY2021-Q2WorsenedAnnual report
「The quarterly net loss was ¥509.697 million.」
The Company also posted a net loss of ¥509 million for the cumulative second-quarter period, and losses continued to be recorded. In addition, amounts were transferred from capital stock and capital surplus to retained earnings to offset the accumulated deficit. - FY2021-Q1WorsenedAnnual report
「The quarterly net loss was ¥308.938 million.」
The Company also posted a net loss of ¥308 million in the first quarter, and the accumulated deficit in retained earnings expanded to ¥7,661.396 million. - FY2020-Q3WorsenedAnnual report
「Retained earnings decreased from negative ¥6,510.444 million at the end of the previous fiscal year to negative ¥7,143.875 million due to a quarterly net loss of ¥633.431 million.」
The Company also posted a net loss of ¥633 million for the cumulative third-quarter period, and the accumulated deficit in retained earnings expanded to ¥7,143.875 million. - FY2020-Q2WorsenedAnnual report
「Retained earnings decreased from negative ¥6,510.444 million at the end of the previous fiscal year to negative ¥6,873.355 million due to a quarterly net loss of ¥362.910 million.」
The Company also posted a net loss of ¥362.910 million for the cumulative second-quarter period, and the accumulated deficit in retained earnings expanded to ¥6,873.355 million. - FY2020-Q1WorsenedAnnual report
「The quarterly net loss was ¥167.196 million.」
The Company also posted a net loss of ¥167 million in the first quarter, and the accumulated deficit in retained earnings expanded to ¥6,677.640 million. - FY2019WorsenedAnnual report
「The Company has recorded a net loss for 9 consecutive fiscal years since the fiscal year ended September 2011, primarily because substantial research and development expenses are recognized in advance. As of the end of the fiscal year, the Company had recorded an accumulated deficit in retained earnings of ¥6,510.444 million.」
The net loss marked the ninth consecutive fiscal year of losses, and the accumulated deficit in retained earnings expanded to ¥6,510.444 million. - FY2019-Q3WorsenedAnnual report
「In addition, the Company recorded extraordinary income of ¥62 million from the gain on the extinguishment of shares held in connection with the absorption-type mergers of 株式会社医業経営研究所 and 株式会社メドセル, ¥32 million from the reversal of the allowance for doubtful accounts and ¥8 million from gains on the sale of investment securities, among other items, as well as an extraordinary loss of ¥22 million in business structure improvement expenses. As a result, the quarterly net loss was ¥807 million.」
Despite recording extraordinary income, the Company posted a quarterly net loss of ¥807 million, resulting in an accumulated deficit in retained earnings of ¥6,522.834 million. - FY2019-Q2WorsenedAnnual report
「In addition, the Company recorded extraordinary income of ¥62 million from the gain on the extinguishment of shares held in connection with the absorption-type mergers of 株式会社医業経営研究所 and 株式会社メドセル, ¥15 million from the reversal of the allowance for doubtful accounts, ¥8 million from gains on the sale of investment securities and ¥4 million from gains on the sale of fixed assets, among other items, as well as an extraordinary loss of ¥10 million in business structure improvement expenses. As a result, the quarterly net loss was ¥499 million.」
Despite recording extraordinary income and other items, the Company posted a quarterly net loss of ¥499 million, and the accumulated deficit in retained earnings was ¥6,214 million on the balance sheet. - FY2019-Q1WorsenedAnnual report
「In addition, the Company recorded extraordinary income of ¥62 million from the gain on the extinguishment of shares held in connection with the absorption-type mergers of 株式会社医業経営研究所 and 株式会社メドセル, ¥14 million from the reversal of the allowance for doubtful accounts, ¥8 million from gains on the sale of investment securities and ¥1 million from the reversal of stock acquisition rights, among other items. As a result, the quarterly net loss was ¥222 million.」
Despite recording extraordinary income, the Company posted a quarterly net loss of ¥222 million, resulting in an accumulated deficit in retained earnings of ¥5,937.995 million. - FY2018-Q3WorsenedAnnual report
「Quarterly net loss attributable to owners of the parent: ¥2,611 million (quarterly net loss attributable to owners of the parent in the same period of the previous year: ¥1,417 million)」
The cumulative net loss attributable to owners of the parent for the third quarter expanded from the same period of the previous year, and the deficit in retained earnings reached ¥5,215.753 million. - FY2018-Q2WorsenedAnnual report
「Quarterly net loss attributable to owners of the parent: ¥2,104 million (quarterly net loss attributable to owners of the parent in the same period of the previous year: ¥991 million)」
The cumulative net loss for the second quarter expanded from the same period of the previous year, and the deficit in retained earnings reached ¥4,708.745 million. - FY2017MaterialisedAnnual report
「Due in part to the front-loading of substantial R&D expenses, the Group has recorded a net loss attributable to owners of the parent for seven consecutive fiscal years since the fiscal year ended September 2011, resulting in a deficit in retained earnings of ¥2,603,990 thousand at the end of the consolidated fiscal year.」
Seven consecutive fiscal years of net losses attributable to owners of the parent and a deficit in retained earnings of ¥2,603,990 thousand have occurred.